

Safety and Efficacy of Dapoxetine in the Treatment of Premature Ejaculation: A Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized Study

Mohammad R Safarinejad^{*,†}

[†]Urology and Nephrology Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran

The aim of the study was to evaluate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) drug dapoxetine in delaying ejaculation in patients with premature ejaculation (PE). A total of 212 potent men with PE were randomly assigned to receive 30 mg orally dapoxetine (group 1, $N = 106$) twice daily or similar regimen of placebo (group 2, $N = 106$) during a 12-week period for each agent. Pretreatment evaluation included history and physical examination, geometric mean intravaginal ejaculatory latency time (IELT, primary outcome measure), and International Index of Erectile Function (IIEF). The efficacy of two treatments was assessed every 2 weeks during treatment, at the end of study, and in 3-month follow-up after cessation of treatment. We measured geometric mean IELT. Thus, the IELT values were logarithmically transformed before statistical analysis and the results are reported as fold increases from baseline with associated 95% confidence intervals (CI). The independent sample two-tailed t -test was used to compare the IELTs. At the end of 12-week treatment, the dapoxetine group had a 2.9- (95% CI, 1.84–4.16) fold increase of the geometric mean IELT, while after placebo the geometric mean IELT did not increase significantly (1.4-fold increase; 95% CI, 0.84–1.63) ($p = 0.001$). The mean weekly intercourse episodes increased from pretreatment values of 1.16 and 1.14 to 2.2 and 1.4, for dapoxetine and placebo, respectively ($p = 0.04$). Baseline mean intercourse satisfaction domain values of IIEF, 12 and 11, reached to 16 and 10 at the 12-week treatment in groups 1 and 2, respectively ($p = 0.04$). At the end of 3-month follow-up period, the geometric mean IELT in dapoxetine and placebo group demonstrated 1.4- (95% CI, 0.66–1.46) and 1.3- (95% CI, 0.77–1.63) fold increase, respectively ($p = 0.1$). Three-month intercourse satisfaction domain value of IIEF was 11 in group 1 and 10 in group 2 ($p = 0.1$). Mean number of adverse events was 19 for dapoxetine and 7 for placebo ($p = 0.02$). Dapoxetine had moderately better results in terms of IELT and intercourse satisfaction vs placebo without long-term benefit for the patient after it is withdrawn. Further studies are necessary to draw final conclusions on the efficacy of this drug in PE.

Neuropsychopharmacology (2008) **33**, 1259–1265; doi:10.1038/sj.npp.1301500; published online 11 July 2007

Keywords: premature ejaculation; treatment; dapoxetine; serotonin; sexual dysfunction

INTRODUCTION

There is limited information concerning the extent of premature ejaculation (PE) in general population. In a random survey of 1511 men in the United States, about one-third considered that they had ejaculated prematurely over the past year (Laumann *et al*, 1999). However, the proportion that perceived their condition as problematic was not stated. Data from the National Health and Social Life Survey have revealed a prevalence of 21% in men aged 18–59 years in the United States (Fisher, 1986). In general,

however, the prevalence of PE is reported as being between 22 and 38% of adult male population (Laumann *et al*, 1999; Spector and Carey, 1990). The World Health Organization (WHO) includes the right to sexual health among its fundamental rights for an individual. There should be 'a freedom from organic disorders, disease, and deficiencies that interfere with sexual and reproductive freedom'. PE has been associated with erosion of sexual self-confidence (Symonds *et al*, 2003) and low sexual satisfaction in men and their female partners (Byers and Grenier, 2003). Ejaculation is affected by numerous mechanisms. Among these, the most accepted and, maybe, the most important one is central serotonin (5-hydroxytryptamine, 5-HT) level. The inhibitory effect of serotonin on libido, ejaculation, and orgasms is well documented and has been attributed to a serotonin-induced decrease in dopamine (a neurotransmitter-enhancing sexual function) level in the central nervous system (Remy, 1986; Baldesarani and Mars, 2003). Selective

*Correspondence: Dr MR Safarinejad, Urology and Nephrology Research Center, Shaheed Beheshti University of Medical Sciences, PO Box 19395-1849, Tehran 1956989333, Iran, Tel: +98 21 2245 4499, Fax: +98 21 2245 6845, E-mail: safarinejad@urologist.md
Received 2 November 2006; revised 27 April 2007; accepted 5 June 2007

serotonin reuptake inhibitors (SSRIs: paroxetine, fluoxetine, sertraline, and citalopram) are reported to be effective for treating PE (Waldinger *et al*, 2004a; Safarinejad and Hosseini, 2006), but they were not developed to treat PE. Probable mechanism of these drugs is the enhancement of net serotonergic transmission by blocking the presynaptic 5-HT (serotonin) uptake site (Waldinger *et al*, 1998a). A member of the well-known SSRI class of compounds, dapoxetine would become the first oral pharmacologic product indicated for the treatment of PE, but at the end of 2005 has not been approved by the FDA as an oral drug for the treatment of PE. Dapoxetine ((+)-(S)-N,N-dimethyl (α)-[2(1-naphthalenyloxy) ethyl]-benzenemethanamine hydrochloride) is an SSRI. Dapoxetine is a fast-acting inhibitor of the serotonin reuptake (Feret, 2005). Dapoxetine is rapidly absorbed after oral administration with a peak plasma concentration occurring between 1.4 and 2.0 h. This is followed by a rapid decline in plasma concentration, to about 5% of peak concentration at 24 h. Both, the area under the curve (AUC) and C_{\max} increase proportionately with doses up to 100 mg. The mean initial half-life of dapoxetine after a single dose is 0.5–0.8 h, and this decreases slightly to 0.4–0.6 h after multiple doses for 6 days. The terminal half-life of dapoxetine is 15–19 h after a single dose and 20–24 after multiple doses (Dresser *et al*, 2004).

Results from placebo-controlled, randomized, multicenter phase-3 trials have demonstrated that men with PE receiving dapoxetine 30 or 60 mg experienced increased intravaginal ejaculatory latency and higher levels of control over ejaculation and satisfaction with sexual intercourse (Pryor *et al*, 2006). In this study, the dose–effect relations were not determined, and the overall dose effect was not reported. One should take the log mean intravaginal ejaculatory latency time (IELT) or the median IELT to compare treatment effects. By comparing the mean IELT values, as the authors have done, there is a considerable risk that dapoxetine seems to induce a far stronger ejaculation delay than actually happens.

In all published studies, treatment and follow-up times have been only weeks, and these studies have been concentrated mainly on short-term effects. Although the therapeutic effect of a drug is seen within weeks, alleviation of problem for a much longer time is required. In some reports, after the end of therapy, the PE recurs in as much as 90% of patients (Grink *et al*, 1996). We need a safe and effective drug indicated specifically for the treatment of PE, especially if it induces long-term benefit for the patient after it is withdrawn. In this study we compared dapoxetine (a fast-acting SSRI) with placebo.

MATERIALS AND METHODS

Study Design

From February 2004 to March 2006 212 potent married men with PE entered the study (mean age 36 years, range 20–55). PE was defined as an IELT of less than 2 min that occurred in more than 90% of intercourses. The IELT was the time between the start of vaginal insertion and the start of intravaginal ejaculation (Waldinger *et al*, 1994). All patients gave their written informed consent to participate in the study after procedures and possible side effects were

explained to them. The study was conducted in accordance with the Declaration of Helsinki and was approved by the local Medical Ethical Committee. At the first visit, patients and wives were interviewed individually by the author and were requested for an independent estimation of the IELT. A stopwatch and instructions on how to measure the IELT were also provided. The patient had to be in a stable relationship with his wife for at least the previous 6 months and possible sexual intercourse equal or greater than 1 per week. Couples were also instructed not to use condoms or topical anesthetic cream, not to pause during intercourse or to have interrupted intromission. Furthermore, they were requested if intercourse took place more than once in a single session, only the first intercourse was measured.

Evaluations

All patients underwent preliminary assessment, including a medical and sexual history, physical examination, and structured interview, diagnosis of mental and physical disorders, IELT, and self-administration of International Index of Erectile Function (IIEF) (Rosen *et al*, 1997). To be able to exclude organic sexual dysfunction, fasting blood glucose level, urine analysis, complete blood count, sex hormones, and prolactin levels were measured. Meares–Stamey test was also performed to exclude genital tract infection. Pretreatment IELT was measured during a 4-week baseline period, during which patients were requested to experience coitus at least four times. All patients were asked to indicate their sexual satisfaction on a scale of 0–5 as proposed by Kim and Paick (1999), with 0 being extremely dissatisfied and 5 extremely satisfied. Pretreatment frequency of sexual intercourse was the mean number of attempts per week during the previous 2 months.

Inclusion/Exclusion Criteria

Only patients without any obvious organic cause of PE and possible sexual intercourse equal to or greater than 1 per week were included. Excluded were those with erectile dysfunction according to IIEF; an organic cause of PE including anatomical abnormalities, genital infection, and neurological disorder; low libido; chronic depression, psychiatric, or physical illness; alcohol, drug, or substance abuse; organic illness causing limitation in SSRI use; use of psychotropic and antidepressant medication; and serious relationship problems. Patients meeting study criteria had their medical and sexual histories and demographic information recorded.

Medical Treatment

Each eligible patient was given a randomization number using an interactive voice response system, which followed a randomization table generated by the method of random permuted blocks (Fleiss, 1986). At baseline (week 0), the patients were randomly assigned to take 30 mg dapoxetine orally twice daily (every 12 h) (group 1), or a similar regimen of placebo (group 2) during the 12-week treatment period. The placebo was a starch compound with the same color and size of dapoxetine. All of the men were asked not to consume alcoholic drinks within 6 h of sexual activity.

Treatment was administered in a randomized sequence that remained unknown to the patient and to the physician. None of the patients underwent formal psychosexual counseling. Persons who were geographically and operationally independent from the study investigator did the randomization of the study. Patients were given a diary to record the frequency of coitus and adverse drug-related effects.

Outcome Measures

Patients were screened on week -4. Baseline measurements were obtained on day -1, and efficacy assessments were made every 2 weeks after the initial dose of dapoxetine on day 1, at the end of 12-week treatment period, and 3 months after the cessation of treatment. For the analysis of efficacy and safety, all patients were assessed in each visit by the author evaluating changes in IELT (primary outcome measure), mean intercourse satisfaction domain, mean weekly coitus episodes (secondary outcome measures), and adverse drug effects. Patients and their wives were interviewed separately.

Statistical Analysis

The study sample size of 212 patients (106 per group) was powered for a difference of approximately 1 standard deviation (SD) between the dapoxetine and placebo group with a statistical power of 85% ($\beta = 0.15$) and assuming an overall 10% dropout rate. As the IELT in individual patients usually follows a skewed distribution, we measured geometric mean IELT instead of mean IELT. Thus, the IELT values were logarithmically transformed before statistical analysis, and the results are reported as fold increases from baseline with associated 95% confidence interval (CI). The independent sample two-tailed *t*-test was used to compare the geometric mean IELTs and frequency of coitus by dapoxetine and placebo. Comparison of sexual satisfaction rates of patients and their wives and comparison of the incidence of side effects were tested using the χ^2 -test. A *p* value less than 0.05 was considered statistically significant. Statistical analysis was performed using the computer statistical package SPSS/10.0 (SPSS, Chicago, IL) and SAS/6.4 (SAS Institute, Cary, NC).

RESULTS

Patient Disposition/Demographics

All patients were seen with their wives and were interviewed about their sexual activity and the patient's ejaculation function. There were no statistical differences in IELT, IIEF, and mean coitus attempts per week in the two groups (Table 1). A total of 212 patients were recruited, but only 189 (89%) completed the whole randomized trial study (93 of 106 in the dapoxetine group and 96 of 106 in the placebo group) (Figure 1). Mean patient age was 35.7 years (range 21–54) in group 1 and 36.3 years (range 19–56) in group 2 ($p = 0.08$ not significant) (Table 1). Twenty-three patients (10.9%) did not complete the study: seven because of a lack of effects (two in the dapoxetine group and five in the placebo group), six because of adverse effects (dapoxetine

Table 1 Patient Characteristics

Variables	Dapoxetine, <i>n</i> = 106	Placebo, <i>n</i> = 106	<i>p</i> -value
Mean age, years (range)			
Patients	35.7 (21–54)	36.3 (19–56)	NS
Partners	29 (20–47)	28 (21–49)	NS
Duration of marriage, years (range)	11 (1–22)	12 (1–21)	NS
Education level (no.)			
Patients			
Lower	22	21	NS
Middle	32	30	NS
Higher	52	55	NS
Partners			
Lower	22	19	NS
Middle	6	28	NS
Higher	58	59	NS
Premature ejaculation (no.)			
Primary	40	43	NS
Secondary	56	53	NS
Never ejaculated intravaginally	10	8	NS

Abbreviation: NS = not significant.

group), and ten lost to follow-up (five in each group). The dropout rates were not significantly different between the two groups ($p = 0.07$). Dropouts were excluded from the final analysis.

Efficacy of Dapoxetine

After 12 weeks of treatment, patients receiving dapoxetine demonstrated significantly improved IELT compared to those receiving placebo. The geometric mean IELT was moderately increased (2.9-fold; 95% CI: 1.84–4.16) in the dapoxetine group, compared to only a gradual and mild increase in the placebo group (1.4-fold increase; 95% CI: 0.84–1.63) ($p = 0.001$) (Tables 2 and 3). The mean pretreatment weekly intercourse episodes were 1.16 per week for dapoxetine compared to 1.14 for placebo. Dapoxetine demonstrated superiority in increasing mean pretreatment coitus frequency. The mean intercourse frequency at 12-week treatment was 2.2 and 1.4 for dapoxetine and placebo, respectively ($p = 0.04$). Baseline and 12-week mean intercourse satisfaction domain values of the IIEF were 12, 11 and 16, 10 in groups 1 and 2, respectively. Dapoxetine group reported significantly greater intercourse satisfaction than those in placebo group ($p = 0.04$) (Table 4). Before treatment, 18 of the 189 patients reported never having experienced intravaginal ejaculation. Intravaginal ejaculation was achieved by 7 of the 10 patients (mean age 28.5 years) who had never achieved it at the end of the treatment with dapoxetine. Intravaginal ejaculation was not achieved

in eight patients (mean age 27.3 years) with placebo. Data analysis did not show any statistically significant difference in men with primary and secondary PE in terms of average baseline or 3-month geometric mean IELT. Similarly, data did not show significant differences in men with primary and secondary PE regarding IELT, IIEF domain, mean weekly coitus episodes, and adverse effects profiles.

In 3-month follow-up of treatment, geometric mean IELT, mean weekly intercourse episodes, and mean intercourse satisfaction domain values of the IIEF did not differ significantly between two treatment groups. At the end of 3-month follow-up period, the geometric mean IELT in dapoxetine and placebo group demonstrated 1.4 (95% CI: 0.66–1.4) and 1.3 (95% CI: 0.77–1.63) fold increase, respectively ($p=0.1$). At 3-month follow-up, the mean intercourse frequency was 1.21 per week for dapoxetine compared to

1.19 per week for placebo ($p=0.1$). The mean intercourse satisfaction domain values of the IIEF at 3-month follow-up were 11 and 10 for dapoxetine and placebo, respectively ($p=0.1$) (Table 4). Erectile dysfunction was not noted with dapoxetine but was noted with placebo in two patients.

Anejaculation did not occur in our patients. Data analysis did not show significant differences in men with primary and secondary PE regarding IELT, IIEF domain, mean weekly coitus episodes, and adverse-effect profiles.

Safety

More adverse effects were associated with dapoxetine treatment ($p=0.02$) (Table 5). Nineteen (20.4%) dapoxetine and seven (7.3%) placebo patients reported treatment-related adverse events; the most common in the dapoxetine group were nausea (5, 5.4%), diarrhea (5, 5.4%), insomnia (4, 4.3%), headache (4, 4.3%), and dizziness (3, 3.2%). Six patients were dropped out of the study because of side effect in dapoxetine group.

DISCUSSION

Before the past decade, the major approach to treating PE was behavioral and psychotherapy, relying on such techniques as the 'pause' and 'squeeze' methods (Masters and Johnson, 1970; Kaplan, 1974). However, the application of the principles of evidence-based medicine shows that there is little evidence to support the psychological approach and behavioral treatment. Dapoxetine gave chronically improved latencies over baseline. However, even at 60 mg, the latencies were still <2 min in most of the patients. We doubt whether greater than this dose is suitable for large-scale use. Prolongation of the ejaculatory interval within few days of treatment suggests that this acute effect is due to direct blocking of central serotonergic reuptake by dapoxetine. Ejaculation is a reflex comprising different sensory pathways, motor centers, and nerve pathways. This ejaculatory reflex has been shown to be controlled primarily by both serotonin and dopamine (McMahon, 2004). Among the different subtypes of 5-HT receptors, the most important ones on ejaculation are 5-HT_{1A}, 5-HT_{1B}, and 5-HT_{2C} receptors (Ahlenius *et al*, 1981). Because the rapid onset of postponement of ejaculation by some of the SSRIs has a similar time course as their synaptic effect on 5-HT, it is suggested that the effect on ejaculation is mediated by acute enhancement of 5-HT neurotransmission or by differential activation of different 5-HT receptor populations, notably 5-HT_{1A} and 5-HT_{2C} receptors (Szele *et al*, 1988; Molewijk *et al*, 1989). Activation of the 5-HT_{1B} receptor also inhibits 5-HT release and male rat ejaculatory behavior (Hillegaart and Ahlenius, 1998). The total absence of ejaculation delay in men who took nefazodone was attributed to its 5-HT_{2C} and 5-HT_{2A} receptor-blocking properties (Waldinger *et al*, 2001). Serotonin binds to 5-HT_{2C} and 5-HT_{1A} receptors to delay ejaculation. Dapoxetine's mechanism of action is the inhibition of neuronal reuptake of serotonin. It was also shown to bind and inhibit the reuptake transporters of dopamine and norepinephrine (Gengo *et al*, 2005). Elimination is biphasic, with an initial half-life of approximately 1.4 h and




Figure 1 Study design.

Table 2 Fold Increase in Geometric Mean IELT

Group	12-week		3-month follow-up		p-value
	Fold increase	95% CI	Fold increase	95% CI	
Dapoxetine	2.9	1.84–4.16	1.4	0.66–1.46	0.001
Placebo	1.4	0.84–1.63	1.3	0.77–1.63	0.1

Abbreviation: IELT, intravaginal ejaculatory latency time.

Table 3 Mean IELT, Frequency of Coitus and Mean Intercourse Satisfaction Domain Values of the IIEF

	Baseline	12-week	p-value	3-month follow-up	p-value
<i>Group 1</i>					
Mean IELT (s)	28	193	0.001	38	0.1
Mean no. of coitus/week	1.16	2.2	0.04	1.21	0.1
Mean intercourse satisfaction domain values of the IIEF	12	16	0.04	11	0.1
<i>Group 2</i>					
Mean IELT (s)	31	54	0.08	37	0.08
Mean no. of coitus/week	1.14	1.4	0.07	1.19	0.09
Mean intercourse satisfaction domain values of the IIEF	11	10	0.09	10	0.09

Abbreviations: IELT, intravaginal ejaculatory latency time; IIEF, international index of erectile function.

Table 4 Sexual Satisfaction Rates of the Patients and Wives

	Satisfied (%)		Moderate satisfied (%)		Dissatisfied (%)	
	Patients	Wives	Patients	Wives	Patients	Wives
Baseline	—	—	—	6	100	94
<i>Group 1</i>						
12-week	74*	69*	14**	14**	12*	17*
3-month follow-up	3**	8**	7**	11**	90**	71**
<i>Group 2</i>						
12-week	18	6	12	12	70	82
3-month follow-up	6	10	10	14	84	76

* $p < 0.001$ vs group 2.

** p = not significant vs group 2.

Table 5 Drug-Related Side Effects

	No. of patients from group 1 (%)	No. of patients from group 2 (%)	p-value
Nausea	5 (5.4)	1 (1)	0.02
Diarrhea	5 (5.4)	0	0.02
Insomnia	4 (4.3)	1 (1)	0.02
Headache	4 (4.3)	1 (1)	0.04
Dizziness	3 (3.2)	0	0.02
Erectile dysfunction	0	2 (2.1)	0.04
Loss of libido	3 (3.2)	2 (2.1)	0.07

a terminal half-life of approximately 20 h. The pharmacokinetics of dapoxetine metabolites, desmethyldapoxetine, and dapoxetine-*N*-oxide, is unaffected by multiple dosing (Modi *et al*, 2006).

This study demonstrated that dapoxetine 30 mg twice daily moderately delays ejaculation in men. A 2.9-fold IELT

increase is really the minimum that is required for the men with genuine PE. For example, a man with a baseline IELT of 10 s will get an ejaculation after 30–40 s when taking this drug. Furthermore, mean weekly intercourse episodes for patients treated with dapoxetine compared to placebo were mildly superior. We also used an inventory for analysis of satisfaction scores for the men or their wives. Satisfaction scores mildly improved with dapoxetine. Although the baseline IIEF erectile function was normal in the two groups, at the end of 12-week treatment period, intercourse satisfaction and overall satisfaction remained low. Men with PE also reported significantly higher problem levels on other aspects of sexual functioning such as difficulty becoming aroused, difficulty discussing sexual problems, satisfaction with sexual intercourse, satisfaction with the sexual relationship, difficulty being able to avoid anxiety about coitus, and problems achieving erections.

Dapoxetine administered increased IELT, as early as after administration of the first dose. The beneficial effects of dapoxetine on outcome measures remain nearly constant after 1-week treatment. In this study, prolong administration of dapoxetine was not associated with further benefit.

Of the SSRIs, paroxetine, sertraline, fluoxetine, citalopram, and tricyclic antidepressants (clomipramine) have all been shown to be effective in the treatment of PE (Safarinejad and Hosseini, 2006; McMahon, 1998; Manasia *et al*, 2003; Sae Chul and Kyung, 1998). Waldinger *et al* (1998b) reported on a study comparing the relative effects of placebo and the SSRI antidepressants: fluoxetine, fluvoxamine, paroxetine, and sertraline on PE. Latencies were increased from a baseline of 18–29 s on placebo and for the SSRIs, 211, 55, 476 and 117 s, respectively. In a study the efficacy and safety of dapoxetine, paroxetine, and placebo were compared for the oral pharmacotherapy of PE (Safarinejad, 2006). Paroxetine provided significantly better results in terms of IELT and intercourse satisfaction vs dapoxetine.

Dapoxetine belongs to the group of SSRIs. The fact that its pharmacokinetic profile is different regarding the duration of half-life and T_{max} does not mean that its pharmacodynamic properties are different.

The clinical data available on dapoxetine are limited to one phase-2 and two phase-3 trials. Hellstrom *et al* (2004) randomized 166 adult heterosexual men in a multicenter, placebo-controlled, double-blind, 3-period, crossover phase-2 study to either dapoxetine 60 mg, dapoxetine 100 mg, or placebo. Intention-to-treat analysis demonstrated significant decreases favoring both doses of dapoxetine for increasing IELT compared to placebo ($p < 0.0001$). Nausea was the most commonly reported adverse effect, occurring with greater frequency in the dapoxetine 100-mg group (16.1%) compared to the 60-mg group (5.6%) and placebo group (0.7%). Pryor *et al* (2006) conducted two randomized, double-blind, placebo-controlled, multicenter studies of identical design in 2614 men diagnosed with PE according to DSM-IV definition, one evaluating the 30-mg dose of dapoxetine and the other evaluating the 60-mg dose. Mean IELT at the baseline was 0.90 (SD 0.47) min, 0.92 (0.59) min, and 0.91 (0.48) min, and at study end point (week 12 or final visit) was 1.75 (2.21) min for placebo, 2.78 (1.48) min for 30 mg dapoxetine, and 3.32 (3.68) min for 60 mg dapoxetine. Nausea was the most common adverse event. Nausea was reported by 20.1% of patients in the 60-mg group and 8.7% of patients in the 30-mg group. IELT distribution behaves positively skewed among the male healthy population and in the individual men (Waldinger *et al*, 2004a). In the above-mentioned studies, the authors did not measure geometric mean IELT. They did not provide confidence intervals of their fold-increase outcomes, which is necessary for a good impression of the potency of the drug.

The notable findings of our study first include the moderate superiority of dapoxetine over placebo in increasing all of the measured parameters (IELT, IIEF, and mean number of coitus episodes weekly). Second, improvement in the above-mentioned parameters was not observed in the 3-month follow-up after cessation of therapy.

The adverse events of dapoxetine are dose dependent. The most common adverse events associated with dapoxetine are nausea, diarrhea, dizziness, and headache (Hellstrom *et al*, 2005). Nausea is fairly significant, with an incidence of 20% reported in patients taking the 60 mg dose of dapoxetine. The rate of nausea in our study was 5.4%. In our study six (2.8%) patients discontinued dapoxetine due to adverse events.

It appears dapoxetine does not provide a clear advantage in improving latency time compared with other SSRIs. Questions regarding the true efficacy of the reported studies without a proper statistical analysis are valid. In the current study, we prescribed dapoxetine (without any sponsorship) in a placebo-controlled fashion to men who reported PE but without any known etiologic factor. However, the beneficial effects of dapoxetine were not produced in the 3-month follow-up after cessation of treatment. Clearly, the issue of placebo-controlled trials will remain the ultimate litmus test of treatment efficacy. However, we present our study as the largest group of men treated and evaluated following the chronic daily dapoxetine therapy. Medical treatment in PE needs careful interpretation with respect to design and methodology of the studies (Waldinger, 2003, 2004). For drug-treatment research, it should be noted that the assessment of delay of IELT depends on gender (male/female), absolute IELT at baseline, tool of assessment (questionnaire, stopwatch), and type of SSRI (Rowland *et al*, 2001; Perelman *et al*, 2004). Nearly all of the current pharmacotherapies for PE are palliative and do not 'treat' or 'cure' the problem actually. We need a safe and effective drug launched specifically for the treatment of PE, which induces long-term benefit for the patient after it is withdrawn.

CONCLUSION

Our results suggest that dapoxetine is no better than other SSRIs in treatment of PE. The real long-term efficiency of dapoxetine was not proved after treatment cessation. Opportunities exist for discovering and developing drugs for PE. The positive results from this drug indicate that clinical experiments should continue with various drug regimens and study settings.

ACKNOWLEDGEMENTS

The investigator is indebted to the patients who participated in this study. We appreciate the encouragement and help provided by coordinators, project managers, and data reviewers. We thank Miss Shiva Safarinejad for her secretarial assistance.

DISCLOSURE/CONFLICT OF INTEREST

We have no disclosures to report. The author declares that, except for the income received from their primary employer, no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional service, and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.

REFERENCES

- Ahlenius S, Larsson K, Svensson L, Hjorth S, Carlsson A, Lindberg P *et al* (1981). Effects of a new type of 5-HT receptor agonist on male rat sexual behavior. *Pharmacol Biochem Behav* 15: 785–792.
- Baldesarani RJ, Mars E (2003). Fluoxetine and side effects. *Arch General Psychiatry* 47: 191–192.

- Byers ES, Grenier G (2003). Premature or rapid ejaculation: heterosexual couples' perceptions of men's ejaculatory behavior. *Arch Sex Behav* 32: 261–270.
- Dresser M, Lindert K, Lin D, Gidwani S, Gupta SK, Modi NB (2004). Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers [abstract]. *Clin Pharmacol Ther* 75: 113.
- Feret B (2005). Focus on dapoxetine: a novel, fast-acting serotonin reuptake inhibitor. *Formulary* 40: 227–230.
- Fisher E (1986). Common sexual problems in general practice. *Aust Fam Physician* 15: 43–47.
- Fleiss J (1986). *The Design and Analysis of Clinical Experiments*. John Wiley & Sons Inc.: New York, NY, pp 49–51.
- Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B (1996). Influence of tramadol on neurotransmitter systems of the rat brain. *Arzneimittelforschung* 46: 1029–1036.
- Gengo PJ, View M, Giuliano F, McKenna KE, Chester A, Lovenberg T (2005). Monoaminergic transport binding and inhibition profile of dapoxetine, a medication for the treatment of premature ejaculation. *J Urol* 173(Suppl): 239. (abstract 878).
- Hellstrom WJ, Althof S, Gittelman M, Steidle C, Ho KF, Kell S *et al* (2005). Dapoxetine for the treatment of men with premature ejaculation (PE): dose-finding analysis. *J Urol* 173(Suppl): 238 (abstract 877).
- Hellstrom W, Gittelman M, Althof S, Ho KF, Kell S (2004). Dapoxetine HCl for the treatment of premature ejaculation: a phase II, randomized, double-blind, placebo-controlled study. *J Sex Med* 1(Suppl): 59. (abstract 097).
- Hillegaart V, Ahlenius S (1998). Facilitation and inhibition of male rat ejaculatory behaviour by the respective 5-HT_{1A} and 5-HT_{1B} receptor agonists. *Brit J Pharmacol* 125: 1733–1743.
- Kaplan HS (1974). *The New Sex Therapy: Active Treatment of Sexual Dysfunctions*. Brunner/Mazel: New York.
- Kim SW, Paick JS (1999). Short-term analysis of the effects of a needed use of sertraline at 5 pm for the treatment of premature ejaculation. *Urology* 54: 544–547.
- Laumann EO, Paik A, Rosen RC (1999). Sexual dysfunction in the United States: prevalence and predictors. *JAMA* 281: 530–544.
- Manasia P, Pomerol J, Ribe N, Gutierrez del Pozo R, Alcover Garcia J (2003). Comparison of the efficacy and safety of 90 vs 20 mg fluoxetine in the treatment of premature ejaculation. *J Urol* 170: 164–165.
- Masters WH, Johnson VE (1970). *Human Sexual Adequacy*. Little, Brown: Boston, pp 92–142.
- McMahon CG (1998). Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. *J Urol* 159: 1335–1338.
- McMahon CG (2004). Pharmacological treatment of ejaculatory disorders. *J Sex Med* (Suppl 1): 19–21.
- Modi NB, Dresser MJ, Lin M, Lin D, Desai D, Gupta S (2006). Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. *J Clin Pharmacol* 46: 301–309.
- Molewijk HF, van den Hoeyden JAM, Olivier B (1989). Lower lip retraction is selectively mediated by activation of the 5-HT_{1A} receptor. *Eur J Neurosci* 214(Suppl 2): 121.
- Perelman M, McMahon CG, Barada JH (2004). Evaluation and treatment of the ejaculatory disorders. In: Lue T (ed). *Atlas of Male Sexual Dysfunction*. Current Medicine, Inc.: Philadelphia, PA, pp 127–157.
- Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Dapoxetine Study Group *et al* (2006). Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. *Lancet* 9: 929–937.
- Remy L (1986). The effect of selective 5HT reuptake inhibitors on 5-methoxy-N,N-dimethyltryptamine induced ejaculation in the rat. *Br J Pharmacol* 87: 639–648.
- Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997). The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. *Urology* 49: 822–830.
- Rowland DL, Cooper SE, Schneider M (2001). Defining premature ejaculation for experimental and clinical investigations. *Arch Sex Behav* 30: 235–253.
- Sae Chul K, Kyung S (1998). Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. *J Urol* 159: 425–427.
- Safarinejad MR (2006). Comparison of dapoxetine and paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. *Clin Neuropharmacol* 29: 243–252.
- Safarinejad MR, Hosseini SY (2006). Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. *Int J Impot Res* 18: 154–169.
- Spector IP, Carey MP (1990). Incidence and prevalence of sexual dysfunctions. A critical review of the empirical literature. *Arch Sex Behav* 19: 389–400.
- Symonds T, Abidin D, Hart K, Althof S (2003). How does premature ejaculation impact a man's life? *J Sex Marital Ther* 29: 361–370.
- Szelb EG, Murphy DL, Garrick NA (1988). Effects of fenfluramine, m-chlorophenylpiperazine and other serotonin-related agonists and antagonists on penile erections in non-human primates. *Life Sci* 43: 1297–1303.
- Waldinger MD (2003). Towards evidence-based drug treatment research on premature ejaculation: a critical evaluation of methodology. *Int J Impot Res* 15: 309–313.
- Waldinger MD (2004). Life-long premature ejaculation: from authority based to evidence based medicine. *Br J Urol, Int Update Series* 93: 201–207.
- Waldinger MD, Berendsen HHG, Blok BFM, Olivier B, Holstege G (1998a). Premature ejaculation and serotonergic antidepressant-induced delayed ejaculation: the involvement of the serotonergic system. *Behav Brain Res* 92: 111–118.
- Waldinger MD, Hengeveld MW, Zwinderman AH (1994). Paroxetine treatment of premature ejaculation: a double-blind, randomised, placebo-controlled study. *Am J Psychiatry* 151: 1377–1379.
- Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B (1998b). Effect of SSRI antidepressants on ejaculation: a double-blind, randomised, placebo controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline. *J Clin Psychopharm* 18: 274–281.
- Waldinger MD, Zwinderman AH, Olivier B (2001). Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. *J Clin Psychopharm* 21: 293–297.
- Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B (2004a). Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. *Int J Impot Res* 16: 369–381.